Mineralys Therapeutics Form 4: CFO Trims Stake by ~36%
Rhea-AI Filing Summary
Mineralys Therapeutics (MLYS) – Form 4 filed 30-Jul-2025
CFO & Secretary Adam S. Levy reported open-market sales of 73,678 common shares across three trading days:
- 28-Jul-2025: 12,946 sh. at a weighted avg. $14.0432
- 29-Jul-2025: 807 sh. at $14.0048
- 30-Jul-2025: 51,500 sh. at $14.7023 and 8,425 sh. at $15.0983
Levy now directly owns 132,934 shares. Arithmetic implies his stake fell from 206,612 to 132,934 shares, a reduction of roughly 36 %. No derivative transactions were reported, and the filing does not state that the sales were executed under a Rule 10b5-1 trading plan.
Positive
- None.
Negative
- CFO Adam Levy sold 73,678 shares (~36 % of prior holdings) in open-market transactions, potentially signaling reduced insider confidence.
Insights
TL;DR: CFO sells ~36 % of holdings; modestly negative insider signal.
The CFO’s sizable disposal of 73.7 k shares within three days, without a disclosed 10b5-1 plan, is often viewed by the market as a lack-of-confidence indicator. While Levy retains 132.9 k shares, selling more than a third of his prior position may pressure sentiment, especially given the absence of offsetting insider buys. With no derivative activity or compensatory context, the transaction is considered material for a mid-cap biotech where insider ownership and alignment matter.
TL;DR: Large discretionary insider sale merits monitoring by investors.
From a governance standpoint, concentrated multi-day selling by a senior executive raises questions about near-term outlook or liquidity needs. Because the form does not flag 10b5-1 protection, these appear to be discretionary trades executed in the open market. Investors should watch for additional sales or company disclosures that might contextualize the move.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 51,500 | $14.7023 | $757K |
| Sale | Common Stock | 8,425 | $15.0983 | $127K |
| Sale | Common Stock | 807 | $14.0048 | $11K |
| Sale | Common Stock | 12,946 | $14.0432 | $182K |
Footnotes (1)
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.20. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.01. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $14.06 to $15.06. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.063 to $15.130. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
